Abciximab, ReoPro, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to tlglycoprotein (GP) lib/Ilia receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to tlvitronectin (a, pj receptor found on platelets and vessel wall endothelial and smooth muscle cells.

The chimeric 7E3 antibody is produced by continuous perfusion in mammalian cell culture. The 47 615 dalton Fab fragmeis purified from cell culture supernatant by a series of steps involving specific viral inactivation and removal proceduredigestion with papain and column chromatography.

ReoPro® is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each single use vial containsmg/mL of Abciximab in a buffered solution (pH 7.2).

Indication and usage

Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischerrcomplications:

* in patients undergoing percutaneous coronary intervention

* in patients with unstable angina not responding to conventional medical therapy when percutaneous corona

intervention is planned within 24 hours

Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary intervention have not beiestablished.

Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.